AUTHOR=Hao Meng , Bian Ting , Fu Guangcheng , Chen Yi , Fang Ting , Zhao Chuanyi , Liu Shuling , Yu Changming , Li Jianmin , Chen Wei 

TITLE=An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice

JOURNAL=Frontiers in Microbiology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1114226

DOI=10.3389/fmicb.2023.1114226

ISSN=1664-302X

ABSTRACT=<p><bold>Instruction:</bold> Rift valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes severe disease in animals and humans. Nevertheless, there are no vaccines applied to prevent RVFV infection for human at present. Therefore, it is necessary to develop a safe and effective RVFV vaccine.</p><p><bold>Methods:</bold> We generated Ad5-GnGcopt, a replication-deficient recombinant Ad5 vector (human adenovirus serotype 5) expressing codon-optimized RVFV glycoproteins Gn and Gc, and evaluated its immunogenicity and protective efficacy in mice.</p><p><bold>Results and Discussion:</bold> Intramuscular immunization of Ad5-GnGcopt in mice induces strong and durable antibody production and robust cellular immune responses. Additionally, a single vaccination with Ad5-GnGcopt vaccination can completely protect interferon-α/β receptor-deficient A129 mice from lethal RVFV infection. Our work indicates that Ad5-GnGcopt might represent a potential vaccine candidate against RVFV. However, further research is needed, first to confirm its efficacy in a natural animal host, and ultimately escalate as a potential vaccine candidate for humans.</p>